LinkedIn Announcement:
December 2, 2024
Pharmidex is excited to share that our Head of Oncology,
Dr. Christopher Ireson, will be attending the
DRUG DISCOVERY Paris: SINGLE CELL GENOMICS forum on 3 December 2024! 🎉
This event, organized by ELRIG UK (https://lnkd.in/enEA8GuS), brings together thought leaders in drug discovery and genomics, focusing on the latest advancements in single-cell technologies.
Dr. Ireson is eager to connect with fellow attendees to discuss cutting-edge research and explore potential collaborations. If you’re attending, he’d be delighted to meet with you, don’t hesitate to reach out or catch him at the event!
#Pharmidex #DrugDiscovery #SingleCellGenomics #OncologyResearch
We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜
We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.
We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.
